Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

January 31, 2013

Conditions
Nutrition Support
Interventions
OTHER

Oliclinomel N4

Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated

OTHER

Compounded ternary parenteral nutrition admixtures

Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days

Trial Locations (1)

Unknown

Shanghai No. 6 Hospital, Shanghai

All Listed Sponsors
lead

Baxter Healthcare Corporation

INDUSTRY

NCT01579097 - Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation | Biotech Hunter | Biotech Hunter